TEM
Analyst day, but make it a personality test
Tempus AI didn’t exactly get one neat, tidy Street verdict. It got the full group chat treatment: TD Cowen said Buy and slapped on a $65 price target, Jefferies came in cold with Underperform, and H.C. Wainwright stayed sunny with Buy and a $95 target.
That’s analyst-speak for: “We all agree this is an interesting story, but we’re wildly split on how fast it becomes a great stock.” Classic Wall Street. Same company, three different vibes.
Why investors should care
Tempus lives in the juicy but tricky intersection of AI and healthcare. That’s the kind of combo that gets investors leaning forward… until they realize the market also wants proof, revenue, and a catalyst with a calendar invite.
The bullish notes point to stronger fundamentals and optimism around recent partnerships. The bearish take is basically, “Cool story, but where’s the next step-change?” That tension matters because stocks like Tempus can move fast when sentiment flips — and analyst calls can be the spark.
The takeaway
You’re looking at a company that still has believers and skeptics in equal measure. If Tempus keeps stacking partnerships and showing its AI tools can turn into real commercial momentum, the bulls get ammo. If not, the bears will keep asking for receipts.
Big picture: this wasn’t one clean upgrade or one brutal downgrade. It was a reminder that Tempus is still in the early, messy part of its market story — and the Street is very much arguing in public about how fast the plot thickens.